The objectives of this survey are to collect data to report the safety and efficacy of Firazyr (Icatibant acetate) in the post-marketing phase in participants diagnosed with Hereditary Angioedema (HAE).
Study Type
OBSERVATIONAL
Enrollment
179
Participants with Hereditary angioedema (HAE) receiving treatment with Icatibant acetate (Firazyr) as prescribed by their physician following locally approved prescribing information.
Nagoya-city
Nagoya, Aichi-ken, Japan
Toyohashi-city
Toyohashi, Aichi-ken, Japan
Maebashi-city
Maebashi, Gunma, Japan
Number of Participants With Adverse Events
An adverse event (AE) is any untoward or undesirable medical occurrence in a participant linked in time with the use of a pharmaceutical/ medicinal product. They are not limited to the events with clear causal relationship with treatment with concerned drug. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.
Time frame: Baseline up to end of the study (up to approximately 68 months)
Number of Participants With Adverse Drug Reaction
An adverse event (AE) is any untoward or undesirable medical occurrence in a participant linked in time with the use of a pharmaceutical/ medicinal product. They are not limited to the events with clear causal relationship with treatment with concerned drug. Adverse drug reaction refers to AE related to administered drug.
Time frame: Baseline up to end of the study (up to approximately 68 months)
Time to Treatment for Attack
Time to treatment for attack defined as the time between the onset of the attack and the first injection of treatment. Time to treatment for attack was assessed and reported.
Time frame: Up to 3 months
Time to First Symptom Relief
Time to first symptom relief defined as the time between the first injection of treatment and first symptom relief. Time to first symptom relief was assessed and reported.
Time frame: Up to 3 months
Time to Complete Resolution of Attack
Time to complete resolution of attack defined as the time between the first injection of treatment and the complete resolution of all symptoms. Time to complete resolution of attack was assessed and reported.
Time frame: Up to 3 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Asahikawa-city
Asahikawa, Hokkaido, Japan
Fukagawa-city
Fukagawa, Hokkaido, Japan
Rumoi-city
Rumoi, Hokkaido, Japan
Sapporo-city
Sapporo, Hokkaido, Japan
Kasama-city
Kasama, Ibaraki, Japan
Maizuru-city
Maizuru, Kyoto, Japan
Kishiwada-city
Kishiwada, Osaka, Japan
...and 8 more locations
Total Duration of Attack
Total duration of attack defined as the time between the onset of the attack and the complete resolution of all symptoms. Total duration of attack was assessed and reported.
Time frame: Up to 3 months